Analysis of the MSK cancer panel data of 2022 [23] revealed ARID1A mutations to be foremost truncating, which leads to inactivation and protein loss through rapid degradation [15, 24, 80, 81, 82, 83]. This evidence concerns the gene ARID1A and cancer.